@article{fdi:010068174,
  title = {{C}linical development of placental malaria vaccines and immunoassays harmonization : a workshop report},
  author = {{C}h{\^e}ne, {A}. and {H}ouard, {S}. and {N}ielsen, {M}. {A}. and {H}undt, {S}. and {D}'{A}lessio, {F}. and {S}irima, {S}. {B}. and {L}uty, {A}drian and {D}uffy, {P}. and {L}eroy, {O}. and {G}amain, {B}. and {V}iebig, {N}. {K}.},
  editor = {},
  language = {{ENG}},
  abstract = {{P}lacental malaria caused by {P}lasmodium falciparum infection constitutes a major health problem manifesting as severe disease and anaemia in the mother, impaired fetal development, low birth weight or spontaneous abortion. {P}revention of placental malaria currently relies on two key strategies that are losing efficacy due to spread of resistance: long-lasting insecticide-treated nets and intermittent preventive treatment during pregnancy. {A} placental malaria vaccine would be an attractive, cost-effective complement to the existing control tools. {T}wo placental malaria vaccine candidates are currently in {P}hase {I}a/b clinical trials. {D}uring two workshops hosted by the {E}uropean {V}accine {I}nitiative, one in {P}aris in {A}pril 2014 and the other in {B}russels in {N}ovember 2014, the main actors in placental malaria vaccine research discussed the harmonization of clinical development plans and of the immunoassays with a goal to define standards that will allow comparative assessment of different placental malaria vaccine candidates. {T}he recommendations of these workshops should guide researchers and clinicians in the further development of placental malaria vaccines.},
  keywords = {{P}lacental malaria ; {V}accine development ; {C}linical trial ; {I}mmunoassays ; {H}armonization ; {EUROPE} ; {AFRIQUE}},
  booktitle = {},
  journal = {{M}alaria {J}ournal},
  volume = {15},
  numero = {},
  pages = {art. 476 [11 p.]},
  ISSN = {1475-2875},
  year = {2016},
  DOI = {10.1186/s12936-016-1527-8},
  URL = {https://www.documentation.ird.fr/hor/fdi:010068174},
}